A B S T R A C T Synthetic ovine corticotropin-releasing factor (CRF) was administered to normal male volunteer subjects as an intravenous bolus or 30-s infusion. Doses of CRF ranging from 0.001 to 30 sg/kg body wt were administered, and plasma immunoreactive (IR)-ACTH and IR-cortisol concentrations were measured. The threshold dose appeared to be 0.01-0.03 ag/kg, the half-maximal dose 0.3-1 sg/kg, and the maximally effective dose 3-10 ug/kg. Basal concentrations of IR-ACTH and IR-cortisol were 14±7.6 pg/ ml (mean±SD) and 5.6±2.2 gg/dl, respectively. IR-ACTH rose as early as 2 min after CRF injection, reached peak levels in 10-15 min, and declined slowly thereafter. IR-cortisol rose at 10 min or later and reached peak levels in 30-60 min. At a dose of 30 jig/ kg, neither IR-ACTH nor IR-cortisol fell from peak levels of 82±21 pg/ml (mean±SE) and 23±1.4 ,g/dl, respectively, during the 2-h course of the experiment, indicating that CRF has a sustained effect on ACTH release and/or a prolonged circulating plasma halflife. There was little or no increase in the levels of other anterior pituitary hormones. At doses of 1 gg/ Preliminary results of these studies were presented by Dr.
INTRODUCTION
Corticotropin-releasing factor (CRF)' is a hypothalamic peptide whose existence had long been postulated (1, 2) . Although it was the first of the releasing factors to be described (3, 4) , it has only recently been isolated from ovine hypothalamic extracts (5) and its primary structure, a single chain of 41 amino acid residues, determined (6) . Ovine CRF has subsequently been synthesized (5, 7) and shown to be active in vitro and in vivo (5, 8) . In addition to its action as an ACTH secretagogue, CRF has been shown to produce a variety of behavioral (9) , metabolic (10) , and hemodynamic (5, 11, 12) changes in animals, depending upon whether it is administered intracerebroventricularly or intravenously. When administered intravenously to urethane-anesthetized rats (5) or to conscious dogs (12) , CRF causes systemic arterial hypotension that is dose dependent and, with large doses of CRF, is profound and prolonged.
The present study was undertaken to establish the dose-response relationship between synthetic ovine CRF (7) , administered as an intravenous bolus, and the release of pituitary ACTH, assessed by measuring concentrations of immunoreactive (IR)-ACTH and IRcortisol in peripheral plasma in normal human subjects. Because of the possibility that hypotension or other potentially harmful side-effects might be encountered, we started with a dose that was -0.1% of the expected threshold dose on the basis of studies in rats (8) and subsequently increased it in threefold increments over a 30,000-fold dose range.
METHODS
Subjects. 29 healthy male volunteer subjects, aged 20 to 46 (mean, 29.7) yr, participated in this study. A pertinent medical history and physical examination were recorded for each subject, and an electrocardiogram, urinalysis, complete blood cell count, and serum chemistry profile were obtained. Subjects who had taken any medication, including cannabis, within the previous 6 wk, who had a history of endocrine, central nervous system, cardiac, hepatic, or renal disease, or who had abnormal laboratory findings were excluded from the study. The urinalysis, complete blood cell count and serum chemistry profile were repeated for each subject the day after each injection.
CRF. Synthetic ovine CRF (7) (lot 96-116-20) was dissolved in sterile 0.001 N HCl, 154 mM NaCl, 0.9% (vol/vol) benzyl alcohol at a concentration of 1 or 3 mg/ml. This stock solution was further diluted with sterile 154 mM NaCl containing 10% (wt/vol) mannitol U. S. Pharmacopeia, 0.25% (wt/vol) human serum albumin U. S. Pharmacopeia and 0.9% (vol/vol) benzyl alcohol. CRF concentrations in the solutions were such that, at any dose, the volume administered was calculated as [(0.01 X kg body wt) X 1 ml] and only rarely exceeded 1 ml. Aliquots of the solutions were transferred to empty, sterile 10-ml vials (Gibco/Invenex Div., Dexter Corp., Chagrin Falls, OH) and were either used immediately, were maintained temporarily (<1 h) at 4VC or were stored frozen at -560C until use. Stored aliquots were thawed only once, immediately prior to use. The vials were prepared and were identified by date and experiment number, but not by the CRF concentration in the contained solution.
Study design. The study was performed in a double-blind fashion: neither the subject nor the attending physician knew whether the vial contained vehicle alone or vehicle-plus-CRF. Each subject was told he would participate in (13) . Subjects were fasted after a light lunch, which was consumed before noon to avoid the reported postprandial rise in plasma ACTH and cortisol (14, 15) .
The experiment was performed with the subject supine. (18, 19) and by RIA3 using antibody IgG-CRF-1 (IgG Corp., Nashville, TN), which was raised in a rabbit to synthetic ovine CRF conjugated to bo-vine thyroglobulin. Ovine CRF (7) (20) . RESULTS CRF in solutions. The concentration of IR-CRF in solutions supposed to contain 3 mg/ml was 100±0% (mean±SEM) of that expected, and 87±4.9% in 1-mg/ ml solutions, both of which were dissolved in 0.001 N HCO and were used both as stock solutions and as injected solutions for the 30-and 10-gg/kg doses, respectively. The IR-CRF concentration was 101±6.2% in solutions of 0.3 mg/ml, 78±6.7% in 0.1-mg/ml solutions, 72±6.8% in 0.03-mg/ml solutions and 48% in a solution supposed to contain 0.01 mg/ml CRF. In infused solutions made up to contain 0.003 mg/ml CRF, solutions administered to achieve a 0.03-gg/kg dose, the concentration of IR-CRF was 63±37% of that expected, and the concentration in a 0.001-mg/ml solution was 30% of that expected. The vehicle alone caused no displacement of l25-Ilabeled CRF from IgGoCRF-1 antibody. The concentration of bioactive CRF in a solution supposed to contain 3 mg/ml was 45(10-113)% (mean and 95% confidence limits) of that expected, 156(91-277)% in a 0.3-mg/ml solution, and 80(34-160)% in a 0.002-mg/ml solution; none of these is significantly different from the expected CRF concentration. These results indicate that recovery of CRF from solutions containing <1 mg/ml CRF is variable and may be suboptimal, even when 0.25% albumin and 10% mannitol are included as carriers. The losses are presumably due to adsorption on glass and plasticware. It is possible that some loss of activity occurred after the CRF was injected, due to additional adsorption to glass and plastic surfaces.
Further studies are required to define systems that are more efficient in preventing loss of CRF in solution. For the purposes of the present study, we have presented the results as though the calculated amounts of CRF were actually administered, including at low doses, where CRF recovery was less than optimal.
IR-ACTH and IR-cortisol in plasma. Basal plasma IR-ACTH, calculated as the mean±SD of all of the -15 min and 0 min values, was 14.1±7.6 pg/ml; basal plasma IR-cortisol was 5.6±2.2 sg/dl. Four subjects had basal IR-ACTH levels > 25 pg/ml and basal IRcortisol levels > 10 ug/dl during one of the experiments in which they participated. The data from those experiments were excluded from further analysis, since the subjects appeared to have been stressed prior to CRF injection.
In subjects who received placebo injections, there was a gradual decline in IR-cortisol ( Fig. 1 ) and, to a lesser extent, IR-ACTH (Fig. 2) , reflecting the normal circadian pattern during this 2-h interval. The lowest doses of CRF, 0.001 and 0.003 Mg/kg body wt, were administered to only two subjects each. They appeared to have no effect on plasma IR-cortisol (Figs. 1, 3 (Fig. 3 ). This directly dose-dependent relationship was more obvious for IR-ACTH ( Fig. 2 ) than for IR-cortisol ( Fig. 1 (Figs. 2, 3) .
Other hormones. We measured serum levels of all other anterior pituitary hormones in the serum of subjects who received the two highest doses of CRF. Serum IR-follicle-stimulating hormone increased only minimally, by 0.7±1 IU/ml, in the first 60 min after 30 Mg/kg CRF and not at all after the 10-Ag/kg dose.
Serum IR-luteinizing hormone increased by only 1.6±1.3 IU/ml during the same interval after the larger dose and not at all after the smaller dose of CRF. The maximum increases above basal levels observed, 1.2 IU/ml for IR-follicle-stimulating hormone and 5.9 IU/ml for IR-luteinizing hormone, were well within the range of spontaneous variation observed in normal men (21) . There was no increase in serum IRthyroid-stimulating hormone or IR-growth hormone and only a slight increase in IR-prolactin (maximum change from base line, 0.8±0.2 U/ml, -3.7±3.1 ng/ ml, and 3.0±0.55 ng/ml, respectively) after 30 pg/kg CRF.
Blood cell count, urinalysis, and serum chemistry. There were no changes in complete blood cell count,
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urinalysis, or serum chemistry that could be attributed to CRF. Signs and symptoms. There were no objective signs or subjective symptoms in any subject who received <1 ug/kg CRF. Even at doses of 30 jg/kg, all signs and symptoms were markedly reduced by administering the CRF as a 30-s infusion, rather than as a bolus injection.
Flushing. Two of five subjects who were given 1 pg/kg, four of five subjects who were given 3 ug/kg, and all of the subjects who received higher doses of CRF had objective facial, neck, and upper chest flushing. This was first observed 30 s to 2 min after injection. Both its severity and its duration seemed dose dependent. At the lowest dose at which it was observed, it lasted -30 min. At the 30-ug/kg dose, it was diminished after^1 h, but was still obvious at the conclusion of the experiment and may have lasted as long as 4 h in some subjects. In the more severe flushing reactions, the subjects' faces appeared edematous. Most of these subjects also felt flushed and warm within 30 s to 1 min after CRF injection. This sensation lasted only 1 to 5 min, even though objective flushing persisted much longer, except in three subjects who received 10 or 30 gg/kg CRF, in whom this sensation persisted up to Because we were aware of the hypotensive effects in animals prior to beginning this study, several precautions were taken. We began with very low doses of CRF, less than we anticipated would have ACTHreleasing activity, let alone hypotensive effects. The dose was increased by threefold increments, and the effects on at least two subjects were analyzed before proceeding to the next highest dose. The subjects remained supine throughout the study to eliminate postural effects, their blood pressure and pulse rate were monitored and recorded automatically at frequent intervals, and the volume of blood removed was replaced with normal saline solution. Thus, we attempted to minimize whatever hypotensive effect CRF might have had, since this was not the object of our investigation and since we did not want to complicate the study by introducing a potential stress.
Nevertheless, some subjects did develop tachycardia and transient hypotension. The changes in mean pulse rate and systolic and diastolic blood pressure for subjects receiving each dose of CRF are shown in Fig. 4 . Pulse rate increased transiently but significantly (P < 0.05) at a CRF dose of 3 Ag/kg or more. At a CRF dose of 30 gg/kg, the pulse rate increased markedly within 2 min and remained elevated for 30 min or more. In contrast, mean systolic blood pressure never fell significantly below that of subjects who received placebo injections at any time after injection of any dose of CRF, and mean diastolic blood pressure was significantly less (P < 0.05) only at 30 and 60 min after the largest dose of CRF. The blood pressure of the placebo group fell during the first 30 to 60 min of the experiment, presumably the effect of supine posture and inactivity. Despite the fact that group mean pressures did not, in general, fall significantly lower than those of subjects who received placebo injections, however, some individual subjects had transient, but significant falls in blood pressure. One subject who received a dose of 10 pressure, and three of six subjects who received placebo injections had falls in blood pressure of 15 mmHg or more.
Some of the subjects felt faint and one actually experienced brief syncope shortly after standing at the completion of the experiment. This was not dose-related (the syncopal episode occurred in a subject who received 0.01 sg/kg), was usually not accompanied by hypotension or tachycardia, and was successfully treated by having the subject lie down for a few minutes and, occasionally, by brisk infusion of an additional 100-200-ml saline solution. Furthermore, it was subsequently successfully prevented by having the subjects flex their leg muscles during the 15-min period of sitting and the 2-min period of standing while vital signs were monitored. All of the subjects felt well when they left the Clinical Research Center and when seen again the next day to have blood drawn for posttreatment analyses.
Other symptoms. Four of the subjects receiving CRF doses of 10 or 30 ,ug/kg reported a cool, "menthol-like" sensation on their tongues and/or palates, and one of them described a similar, "cool breeze" sensation in his ears. On two occasions, during which he received injections of 3 and 10 pig/kg CRF, one subject who had chronic allergic rhinitis reported sudden, transient reduction in nasal stuffiness. In every instance, these sensations were reported 30 s to 2 min after CRF injection and lasted only 1 to 2 min. Two subjects who received a 30-,ug/kg dose of CRF had increased peristalsis for 1 h, felt they needed to have a bowel movement, but produced only explosive flatus. One of these subjects also had increased peristalsis of a milder degree after receiving a placebo injection, however. One of these subjects and a subject who received 0.3 ;tg/kg CRF experienced transient nausea within 1 min of injection. One of the subjects who received a bolus injection of 30 ;tg/kg CRF felt a sense of impending doom in the first few minutes after the drug was given. He volunteered immediately thereafter, however, for a second experiment. Except for this, none of the subjects reported any unusual thoughts or emotions, and none exhibited any behavioral changes suggestive of a stress response (9) . In fact, some of them dozed intermittently or constantly throughout the experiment.
DISCUSSION
Secretion by the anterior pituitary gland of ACTH and other peptides derived from proopiolipomelanocortin (proOLMC) [i.e., y-melanocyte-stimulating hormone (yMSH), f3-lipotropin (j3LPH), yLPH, and fl-endorphin] is thought to be controlled by a number of factors, the most important of which are CRF and glucocorticoids. CRF is secreted by cells in the parvicellular portion of the paraventricular nucleus of the hypothalamus (22) and is released into the hypothalamic-hypophysial portal venous system. Its presumed role is one of stimulating proOLMC peptide secretion in a variety of physiological situations, including maintaining the circadian rhythm and responding to stimuli 592 Orth et al.
that are in one way or another perceived as stressful to the organism, such as hypotension, hypoglycemia, and physical or psychological trauma. The major effect of glucocorticoids, cortisol, in the case of man, appears to be to inhibit proOLMC secretion by blocking the action of CRF (8) and, possibly, other secretagogues, such as vasopressin (23), on the pituitary corticotroph; glucocorticoids may also inhibit secretion of CRF by the hypothalamus (2) . Although this overall schema has generally been accepted for more than 25 years and although CRF was the first of the putative hypothalamic releasing factors to be looked for, CRF eluded final purification and structural analysis until 1981, when it was isolated from ovine hypothalamic extract (5) . It has since been synthesized (5, 7) and shown to be active in vitro (5) and in vivo (8) . The action of CRF, which apparently involves generation of intracellular adenosine 3',5'-monophosphate (24) , can be inhibited by prior exposure to glucocorticoids, such as dexamethasone (8) .
In this study, we examined the dose-response relationship of administered synthetic ovine CRF to pituitary ACTH release, as manifested by changes in concentrations of plasma IR-ACTH and IR-cortisol. We chose late afternoon, rather than morning (25) , as the time for conducting these studies in order to take advantage of the relatively low, stable basal secretion of ACTH and cortisol that could be expected at this point in the normal circadian rhythm. Results in normal subjects given placebo injections confirmed this expectation.
Previous studies had indicated that the threshold intravenous dose of CRF was -0.04 ug/kg body wt in unanesthetized, chronically cannulated rats (8) and -0.5,ug/kg in stalk-sectioned macaques (26) . These doses can be estimated to have resulted in initial plasma levels of '400 pg/ml and 5 ng/ml, or -100 pM and 1 nM, respectively. The minimally effective dose of CRF in vitro had been found to be <10 pM in rat anterior pituitary cell cultures (5) and -2 nM in mouse AtT20/D16-16 anterior pituitary tumor cells (27 as contributing to the total IR-ACTH response after high doses of CRF. However; there was no apparent correlation between the magnitude of the IR-ACTH increment and subjective or objective manifestations of stress in individual subjects, no apparent difference in IR-ACTH increments after bolus injections vs. 30-s infusions of CRF, despite the fact that the latter produced less symptoms, and no increase in serum IR-GH, which is generally thought to be a sensitive index of stress, in any of the subjects receiving the highest two doses of CRF. We elected not to administer CRF in doses >30 ag/kg (-2.25 mg total dose) because of the risk of hypotension. Although this is a large mass of peptide to administer, it represents only 0.48 mmol of CRF. For comparison, standard 200-sg diagnostic doses of thyrotropin-releasing hormone and luteinizing hormone-releasing hormone represent 0.55 and 0.17 mmol, respectively, of those peptides.
Establishing the exact dose-response curve was further complicated by the fact that CRF appeared to exert its effects for a prolonged period of time. Thus, the area under the curve of IR-ACTH level vs. time ( Fig. 2 ) continued to increase with higher CRF doses, although the initial peak level of IR-ACTH no longer increased. Based on the maximum level of IR-ACTH attained within the first 15 min, it appears that 0.01-0.03 ;&g/kg was the minimally effective dose, 0.3-1 jg/kg was the half-maximal dose, and 3-10 ,g/kg was the maximally effective dose of synthetic ovine CRF. The dose-response curve appeared to cover a 20-fold range in macaques (26) and at least a 100-fold range in rats (8) . Our results suggest that the range is at least 300-to 1,000-fold in man.
The maximum rate of increase in plasma IR-ACTH during the first 5 to 10 min appeared to be independent of the CRF dose. This suggests that any effective dose of CRF stimulates release of ACTH at a maximum, very rapid rate. Larger doses of CRF sustained this maximum ACTH release rate for longer periods of time. After peak IR-ACTH levels were achieved, they declined at a fairly constant rate of --15 pg/ml. h for CRF doses of 3 jig/kg or less. The decline in IR-ACTH was slower than can be accounted for by the plasma disappearance half-time of ACTH itself, which is '20 to 40 min (13, 28) , depending upon the specific RIA. Thus, the data indicate that additional ACTH was being secreted even as plasma IR-ACTH levels were falling. They further suggest that ovine CRF has a sustained effect on ACTH release and/or a prolonged biologic half-life in human circulating plasma, as has been described in macaques (29) . In these animals, the plasma half-life was found to be '200 min. Our indirect evidence suggests that it is -60 min in man.
Peak levels of IR-ACTH (82±21 pg/ml) achieved within 120 min after injection of the 30-,ug (26) . Our data are in agreement with preliminary results in six normal subjects given smaller doses of CRF (25) . The reason for the difference between humans and monkeys is not clear, but may represent species specificity of certain actions of CRF, species differences in response to CRF, or differences in the model system (i.e., stalk-sectioned, restrained macaques vs. intact, unrestrained humans). These results indicate that in man, CRF is a highly specific secretagogue that acts only on the corticotrophs to release ACTH. However, other effects on the pituitary of males, such as inhibiting basal or stimulated release of other hormones, or different effects on female pituitaries have not been excluded by this study.
At these same doses, CRF did produce other effects. The most prominent and consistent of these was facial flushing. This has been observed after administration of a variety of other peptides (34) , so that it seems unlikely that it is a specific effect of CRF. The mechanism by which the flush is produced by any of these agents is unknown, however. In the case of CRF, it is interesting to speculate on whether this effect might be mediated by the same mechanism that causes the increase in mesenteric blood flow and, thus, results in systemic arterial hypotension. Ovine CRF has strong sequence homology (5) with sauvagine, a 40-residue peptide recently isolated from the skin of the South American frog, Phyllomedusa sauvagei (35) . Sauvagine not only releases ACTH and f3-endorphin in vitro and in vivo, but is an even more potent hypotensive agent, also via the mechanism of enhanced mesenteric blood flow (36) . CRF, on the other hand, is -100 times more potent as an ACTH secretagogue than as a hypotensive agent in the rat (5) . Despite our concern that ovine CRF might act as sauvagine in man, hypotension was not an important problem in these subjects or in two patients with Cushing's disease (37) . When examined as groups, the only significant difference between the post-CRF blood pressures in subjects who were given high doses of CRF and those who received placebo injections was in the diastolic pressure 30 and 60 min after the highest CRF dose. There was significant tachycardia, however, which may have represented a compensatory response to decreased atrial filling. Furthermore, individual subjects did have falls in systolic and diastolic blood pressure of as much as 29 and 24 mmHg, respectively. Since we used an experimental protocol designed to minimize the possibility of significant hypotension, we conclude that caution must be taken when administering CRF to human subjects, until its hemodynamic effects are more fully defined.
In summary, synthetic ovine CRF appears to be a potent and specific ACTH secretagogue in man. It seems to have a prolonged half-life in circulating plasma and a sustained stimulatory effect on ACTH secretion. It produces vasomotor effects, including systemic arterial hypotension, at higher doses. Administered with proper precautions, however, CRF promises to be a safe and very useful investigative, diagnostic and, possibly, therapeutic agent in man.
